Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|July 29, 2022
Survey from Qualio Finds 50%+ of U.S. Consumers Refuse To Use a Healthcare Prescription or Product After a Recall
Advertisement
Qualio — the trusted cloud quality management system software for the entire life sciences ecosystem — announced a new survey of 2,002 U.S. consumers of healthcare products.
Qualio led this survey to better understand how far-reaching quality-related product recalls are when it comes to consumer trust and healthcare-specific purchasing decisions.
The survey uncovered that recalls and related quality issues have a pronounced and enduring impact on purchases of drugs, devices, therapies, and other healthcare products. Overall, survey data found that more than half (51%) of U.S. adults are unlikely to use a prescription drug that has experienced a recall, regardless of whether that issue was fixed. The same amount (51%) also indicated they'd unlikely use a recalled non-prescription healthcare product (e.g., over-the-counter medication, supplements/vitamins, skin products) after a recall.
For more insights and data from this survey, please visit
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
4
Evidence With Purpose: Making Real-World Research Better, Not Just Faster
5